UY26723A1 - Moléculas mutantes de ctla4 solubles y usos de las mismas - Google Patents

Moléculas mutantes de ctla4 solubles y usos de las mismas

Info

Publication number
UY26723A1
UY26723A1 UY26723A UY26723A UY26723A1 UY 26723 A1 UY26723 A1 UY 26723A1 UY 26723 A UY26723 A UY 26723A UY 26723 A UY26723 A UY 26723A UY 26723 A1 UY26723 A1 UY 26723A1
Authority
UY
Uruguay
Prior art keywords
soluble ctla4
mutant molecules
amino acid
molecules
ctla4 mutant
Prior art date
Application number
UY26723A
Other languages
English (en)
Spanish (es)
Inventor
Peter S Linsley
Bajorath Jurgen
Robert J Peach
Joseph R Naemura
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of UY26723A1 publication Critical patent/UY26723A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY26723A 2000-05-26 2001-05-23 Moléculas mutantes de ctla4 solubles y usos de las mismas UY26723A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26

Publications (1)

Publication Number Publication Date
UY26723A1 true UY26723A1 (es) 2001-12-28

Family

ID=26908652

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26723A UY26723A1 (es) 2000-05-26 2001-05-23 Moléculas mutantes de ctla4 solubles y usos de las mismas

Country Status (41)

Country Link
EP (3) EP3029062A1 (instruction)
JP (1) JP4328525B2 (instruction)
KR (2) KR100889887B1 (instruction)
CN (2) CN101255192A (instruction)
AR (1) AR031699A1 (instruction)
AT (1) ATE271066T1 (instruction)
AU (2) AU2001263466C1 (instruction)
BE (1) BE2011C041I2 (instruction)
BR (1) BRPI0111191B8 (instruction)
CA (1) CA2409748C (instruction)
CY (2) CY2011019I2 (instruction)
CZ (1) CZ304451B6 (instruction)
DE (2) DE60104282T2 (instruction)
DK (1) DK1248802T3 (instruction)
EC (1) ECSP024365A (instruction)
EE (2) EE05557B1 (instruction)
EG (1) EG24459A (instruction)
ES (2) ES2571852T3 (instruction)
FR (1) FR11C0053I2 (instruction)
GE (1) GEP20053658B (instruction)
HK (1) HK1048126B (instruction)
HU (2) HU228137B1 (instruction)
IL (1) IL152315A (instruction)
LT (1) LT5133B (instruction)
LU (1) LU91902I2 (instruction)
LV (1) LV12994B (instruction)
MX (1) MXPA02011534A (instruction)
MY (1) MY136113A (instruction)
NO (2) NO330797B1 (instruction)
PE (1) PE20011338A1 (instruction)
PL (1) PL206267B1 (instruction)
PT (1) PT1248802E (instruction)
RU (1) RU2283847C2 (instruction)
SI (1) SI1248802T1 (instruction)
SK (1) SK288131B6 (instruction)
TR (1) TR200402703T4 (instruction)
TW (2) TWI314933B (instruction)
UA (1) UA87432C2 (instruction)
UY (1) UY26723A1 (instruction)
WO (1) WO2001092337A2 (instruction)
ZA (1) ZA200208944B (instruction)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
DE60135029D1 (de) * 2000-07-03 2008-09-04 Bristol Myers Squibb Co Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
PT1397153E (pt) 2001-05-23 2008-06-12 Bristol Myers Squibb Co Métodos para proteger um transplante alogénico de ilhéus utilizando moléculas mutantes de ctla4 solúveis
AU2003243152A1 (en) * 2002-04-19 2003-11-03 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
KR101088223B1 (ko) * 2002-12-23 2011-11-30 브리스톨-마이어스 스큅 컴퍼니 단백질 생산을 위한 포유류 세포 배양 방법에서의 생산물품질 향상
KR20050088136A (ko) 2002-12-23 2005-09-01 브리스톨-마이어스 스큅 컴퍼니 단백질 생산을 위한 포유류 세포 배양 방법
EP1578782A4 (en) 2002-12-30 2007-09-12 Amgen Inc COSTIMULATING FACTORIAL THERAPY
CA2543484C (en) 2003-10-27 2014-02-04 Amgen Inc. Modulation of immune response to an immunogen with ctla-4 and tnfbp
PL2253644T3 (pl) 2005-12-20 2014-04-30 Bristol Myers Squibb Co Kompozycje i sposoby wytwarzania kompozycji
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
WO2008076487A2 (en) 2006-12-20 2008-06-26 Verenium Corporation Antibodies and methods for making and using them
EP2612867A1 (en) 2007-11-01 2013-07-10 Perseid Therapeutics LLC Immunosuppressive polypeptides and nucleic acids
WO2010040105A2 (en) * 2008-10-02 2010-04-08 Trubion Pharmaceuticals, Inc. Cd86 antagonist multi-target binding proteins
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
CN102822198B (zh) 2010-03-12 2016-08-31 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途
US20120214204A1 (en) 2011-02-23 2012-08-23 Amgen Inc. Cell culture media for uvc exposure and methods related thereto
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
US9758566B2 (en) 2012-03-29 2017-09-12 The General Hospital Corporation Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
ES2777778T3 (es) 2012-05-11 2020-08-06 Medimmune Ltd Variantes de CTLA-4
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
WO2014004857A1 (en) * 2012-06-27 2014-01-03 Orban Biotech Llc Ctla4 fusion proteins for the treatment of diabetes
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
CN112481337B (zh) 2014-01-13 2024-06-25 美国安进公司 调控鸟氨酸代谢以操控重组蛋白的高甘露糖糖型含量
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
HUE066803T2 (hu) 2014-06-04 2024-09-28 Amgen Inc Emlõs sejtkultúrák begyûjtésére szolgáló módszerek
EP3680344A1 (en) 2014-12-01 2020-07-15 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
US10590457B2 (en) 2015-02-11 2020-03-17 Bristol Myers-Squibb Company Compositions for cell culture and methods of using the same
RS61943B1 (sr) 2015-04-17 2021-07-30 Alpine Immune Sciences Inc Imunomodulatorni proteini sa prilagodljivim afinitetima
EP3702470A3 (en) 2015-09-09 2020-10-07 The Trustees of Columbia University in the City of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
KR20180073693A (ko) 2015-11-09 2018-07-02 브리스톨-마이어스 스큅 컴퍼니 Cho 세포에서 생산되는 폴리펩티드의 품질 속성을 조작하는 방법
CA3036997A1 (en) * 2016-09-19 2018-03-22 Oncoimmune, Inc. Cytotoxic t-lymphocyte-associated antigen-4(ctla-4)-fc fusion proteins and use thereof for treating adverse events associated with cancer immunotherapy
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
CA3060630A1 (en) 2017-04-20 2018-10-25 Egenesis, Inc. Methods for generating genetically modified animals
KR102813968B1 (ko) 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
BR112020013236A2 (pt) 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
CN115227824A (zh) * 2018-11-12 2022-10-25 中南大学湘雅二医院 免疫检查点的抑制剂在制备治疗青光眼和其他眼部免疫损伤机制相关疾病药物中的应用
US20220281939A1 (en) 2019-08-27 2022-09-08 Tonix Pharma Limited Modified tff2 polypeptides
MY193353A (en) 2019-12-06 2022-10-06 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
WO2021226444A2 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
IL299060A (en) 2020-06-18 2023-02-01 Regeneron Pharma A heavy peptide approach for accurate measurement of lysine with an unprocessed carboxyl terminus
JP2023537670A (ja) 2020-07-28 2023-09-05 シージェン インコーポレイテッド ポリペプチドを生産するための方法及びシステム
US20250040546A1 (en) 2021-12-16 2025-02-06 Bristol-Myers Squibb Company Detergent for viral inactivation
WO2023167857A1 (en) 2022-03-02 2023-09-07 Regeneron Pharmaceuticals, Inc. Cell culture methods for antibody production

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
DK0606217T4 (da) 1991-06-27 2009-03-30 Bristol Myers Squibb Co CTL4-receptor, fusionsproteiner indeholdende den samt anvendelse deraf
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
AU1102000A (en) * 1998-10-07 2000-04-26 Millennium Pharmaceuticals, Inc. Novel th2-specific molecules and uses thereof
DE60135029D1 (de) * 2000-07-03 2008-09-04 Bristol Myers Squibb Co Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis

Also Published As

Publication number Publication date
LT5133B (lt) 2004-05-25
AR031699A1 (es) 2003-10-01
BR0111191A (pt) 2004-07-06
DE122011100063I1 (de) 2012-06-14
CY1117625T1 (el) 2017-04-26
KR20030009502A (ko) 2003-01-29
FR11C0053I1 (instruction) 2012-01-13
BE2011C041I2 (instruction) 2020-08-20
ATE271066T1 (de) 2004-07-15
EP1248802A2 (en) 2002-10-16
EP1248802B9 (en) 2005-05-11
IL152315A (en) 2010-04-15
EP1536234A3 (en) 2009-06-03
EP1248802B1 (en) 2004-07-14
PL206267B1 (pl) 2010-07-30
NO20025656L (no) 2002-11-25
KR100895134B1 (ko) 2009-05-04
NO330797B1 (no) 2011-07-18
HK1048126A1 (en) 2003-03-21
EP1536234B1 (en) 2016-03-16
EP3029062A1 (en) 2016-06-08
NO2011027I2 (instruction) 2011-12-15
ECSP024365A (es) 2003-03-31
AU6346601A (en) 2001-12-11
HUS1300012I1 (hu) 2016-08-29
PT1248802E (pt) 2004-11-30
HU228137B1 (en) 2012-12-28
DK1248802T3 (da) 2004-11-15
TWI314933B (en) 2009-09-21
CZ304451B6 (cs) 2014-05-14
CN1441810A (zh) 2003-09-10
BRPI0111191B1 (pt) 2019-12-31
MY136113A (en) 2008-08-29
CA2409748A1 (en) 2001-12-06
CY2011019I1 (el) 2016-12-14
TR200402703T4 (tr) 2004-11-22
SK288131B6 (sk) 2013-10-02
WO2001092337A3 (en) 2002-05-10
CZ20023892A3 (cs) 2003-09-17
HUP0302201A3 (en) 2010-01-28
AU2001263466B2 (en) 2006-04-27
MXPA02011534A (es) 2004-08-12
PL366231A1 (en) 2005-01-24
FR11C0053I2 (fr) 2013-01-11
EE05458B1 (et) 2011-08-15
DE60104282T2 (de) 2005-10-13
EG24459A (en) 2009-07-16
ES2225549T3 (es) 2005-03-16
CA2409748C (en) 2008-09-16
IL152315A0 (en) 2003-05-29
EE05557B1 (et) 2012-08-15
HUP0302201A2 (hu) 2003-10-28
EE200200659A (et) 2004-06-15
NO20025656D0 (no) 2002-11-25
TWI319405B (en) 2010-01-11
GEP20053658B (en) 2005-11-10
CN101255192A (zh) 2008-09-03
ZA200208944B (en) 2004-02-13
RU2283847C2 (ru) 2006-09-20
CY2011019I2 (el) 2016-12-14
DE60104282D1 (de) 2004-08-19
WO2001092337A2 (en) 2001-12-06
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
NO2011027I1 (no) 2012-01-09
HK1048126B (en) 2005-03-04
ES2571852T3 (es) 2016-05-27
CN1309735C (zh) 2007-04-11
AU2001263466C1 (en) 2006-10-26
JP2004511213A (ja) 2004-04-15
TW200906857A (en) 2009-02-16
UA87432C2 (uk) 2009-07-27
PE20011338A1 (es) 2002-01-13
LV12994B (en) 2003-08-20
SK15702002A3 (sk) 2004-01-08
BRPI0111191B8 (pt) 2021-05-25
HK1071931A1 (en) 2005-08-05
JP4328525B2 (ja) 2009-09-09
EE201100050A (et) 2011-10-17
LT2002114A (en) 2003-12-29
EP1536234A2 (en) 2005-06-01
SI1248802T1 (en) 2005-02-28
KR100889887B1 (ko) 2009-03-24

Similar Documents

Publication Publication Date Title
UY26723A1 (es) Moléculas mutantes de ctla4 solubles y usos de las mismas
CY1106532T1 (el) Ετερολογος εκφραση των πρωτεϊνων της neisseria
ATE376026T1 (de) Klebstoffzusammensetzungen mit selbstorganisierenden molekülen, klebstoffe, gegenstände und verfahren
BR0107691A (pt) Sapogeninas substituìdas e seu uso
WO2005014049A3 (en) Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
ATE407697T1 (de) Erythropoietin immunglobulin fusionsproteine
DK0842934T3 (da) 5-HT1F agonister
CY1105944T1 (el) Βιοαποικοδομησιμα αλγινικα πηκτωματα παρατεταμενης εκλυσης
DK1329458T3 (da) Peptider som sænker blodglucoseniveauer
CY1105020T1 (el) Υποκαταστατες διαζεπανες
DK1107996T3 (da) Humane anti-faktor IX/IXa-antistoffer
DE69636285D1 (de) ISOLIERTES FrpB NUKLEINSÄUREMOLEKÜL UND ENTSPRECHENDE IMPFSTOFF
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
SE0003476D0 (sv) Compounds
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
BR9812773A (pt) "alfa-amino-epsilon-caprolactamas policìclicas e compostos relacionados"
ATE388227T1 (de) Gemisch mindestens zweier fusionsproteine sowie ihre herstellung und verwendung
NO20002408D0 (no) 5-HT1F antagonister

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20140306

VENC Patent expired

Effective date: 20210523